Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.

Alla Zorina, Vadim Zorin, Artur Isaev, Dmitry Kudlay, Natalia Manturova, Andrei Ustugov, Pavel Kopnin

Abstract readReview

In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025
Review
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase.EClinicalMedicine · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alla ZorinaArtgen Biotech, Moscow 119333, Russia.

Vadim ZorinArtgen Biotech, Moscow 119333, Russia.

Artur IsaevArtgen Biotech, Moscow 119333, Russia.

Dmitry KudlayDepartment of Pharmacology, The I. M. Sechenov First Moscow State Medical University (The Sechenov University), Moscow 119991, Russia.

Natalia ManturovaDepartment of Plastic and Reconstructive surgery, Cosmetology and Cell Technologies, Pirogov Russian National Research Medical University, Moscow 117997, Russia.

Andrei UstugovDepartment of Plastic and Reconstructive surgery, Cosmetology and Cell Technologies, Pirogov Russian National Research Medical University, Moscow 117997, Russia.

Pavel KopninScientific Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0002-2078-4274

Funding

Russian Science Foundation 23-15-00433

6 · The paper itself

Abstract

This detailed review describes innovative strategies and current products for gene and cell therapy at different stages of research and development to treat recessive dystrophic epidermolysis bullosa (RDEB) which is associated with the functional deficiency of collagen type VII alpha 1 (C7) caused by defects in the

Indexed as

Cell- and Tissue-Based TherapyCollagen Type VIIEpidermolysis Bullosa DystrophicaGenetic TherapyAnimalsGene EditingHumansKeratinocytesCOL7A1 protein, humanCollagen Type VIICOL7A1epidermolysis bullosagene and cell therapygene deliveryskinstem cellsstudy outcomestreatment

Identifiers

PMID39408598

DOI10.3390/ijms251910270

PMCPMC11476579

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.